GlassScriptPhysician profile
Eileen Limchoa
NPI 1225640030
$593.48
in general payments reported to CMS, 2019-2025
13 companies · $470 in 2025
The $470 reported for 2025 was more than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $123 · 2025: $470.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $593.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $593.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $154.17 | 2025 | Fintepla, Briviact, Rystiggo |
| Acadia Pharmaceuticals INC | $90.94 | 2025 | Nuplazid |
| Sk Life Science, INC. | $63.92 | 2024-2025 | |
| Abbvie INC. | $60.56 | 2024-2025 | |
| Xeris Pharmaceuticals, INC. | $35.65 | 2025 | Keveyis |
| Vanda Pharmaceuticals INC. | $35.37 | 2025 | Ponvory |
| Takeda Pharmaceuticals U.S.A., INC. | $33.28 | 2024 | Hyqvia |
| Otsuka America Pharmaceutical, INC. | $26.55 | 2024 | Rexulti |
| Janssen Biotech, INC. | $22.89 | 2025 | |
| Lundbeck LLC | $20.09 | 2025 | Vyepti |
| Eisai INC. | $17.48 | 2025 | |
| Jazz Pharmaceuticals INC. | $16.48 | 2025 | |
| Astrazeneca Pharmaceuticals LP | $16.10 | 2025 | Wainua |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eileen Limchoa listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.